This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...

書目詳細資料
Main Authors:	Ryder, R, Holman, R, Gwilt, M
格式:	Conference item
出版:	Association of British Clinical Diabetologists 2016

相似書籍

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
由: Holman, R, et al.
出版: (1987)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
由: André J. Scheen
出版: (2021-01-01)

Sulphonylurea therapy over six years does not delay progression to diabetes
由: Herlihy, O, et al.
出版: (2000)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
由: Cull, C, et al.
出版: (2000)

Sulphonylureas and hypoglycaemia.
由: Ferner, R, et al.
出版: (1988)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
由: Eeley, E, et al.
出版: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
由: Matthews, DR, et al.
出版: (1998)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
由: Huri, H.Z., et al.
出版: (2010)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
由: Eeley, E, et al.
出版: (1996)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
由: Misra, S, et al.
出版: (2018)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
由: Turner, R, et al.
出版: (1998)

New uses for old drugs: neonatal diabetes and sulphonylureas.
由: Ashcroft, F
出版: (2010)

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor
由: Peter Proks
出版: (2013-06-01)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
由: Matthews, DR, et al.
出版: (1998)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
由: Rachman, J, et al.
出版: (1996)

Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes.
由: Woodcock, A, et al.
出版: (2007)

Should I believe all the truths?
由: Greenberg, A
出版: (2018)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
由: Pearson, E, et al.
出版: (2007)

Stem cells in cancer : should we believe or not? /
由: Grande, Enrique, et al.
出版: (2014)

Sulphonylureas and the rise and fall of beta-cell function
由: Matthews, DR, et al.
出版: (2005)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
由: Rashida Vasanwala MD (Paeds), MRCPCH (UK), et al.
出版: (2010-06-01)

The clinical aspects ot the sulphonylurea compounds from the position of the cardioprotective approach at patient with type 2 diabetes, using glucocardiomonitoring
由: N. A. Chernikova, et al.
出版: (2022-10-01)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
由: Degli Esposti L, et al.
出版: (2014-10-01)

Interactions between nicorandil and sulphonylureas: a structural basis.
由: Reimann, F, et al.
出版: (2001)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
由: Chelsea Baker, et al.
出版: (2021-01-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
由: Fournier, Marie, et al.
出版: (2014-10-01)

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
由: Ammälä, C, et al.
出版: (1996)

Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
由: Geoffrey Hackett
出版: (2020-07-01)

Homozygous hypomorphic HNF1A alleles are a novel cause of young-onset diabetes and result in sulphonylurea sensitive diabetes
由: Misra, S, et al.
出版: (2020)

Effects of protein phosphorylation on the sulphonylurea receptor of the pancreatic beta-cell.
由: Niki, I, et al.
出版: (1997)

Binding of sulphonylureas to plasma proteins – a KATP channel perspective
由: Proks, P, et al.
出版: (2018)

Alternative MDR splicing is required for direct potentiation of exocytosis by sulphonylureas
由: Wendt, A, et al.
出版: (2001)

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
由: Peter Proks, et al.
出版: (2018-01-01)

Should an echocardiographic scan be done routinely for infants of diabetic mothers?
由: M Vural, et al.
出版: (1995-10-01)

A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
由: Proks, P, et al.
出版: (2006)

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
由: Hansen, A, et al.
出版: (2002)

To believe or not to believe
由: Chistine Kuruç
出版: (1989-12-01)

Continued Dispensing: what medications do patients believe should be available?
由: Salem Hasn Abukres, et al.
出版: (2015-05-01)

Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region
由: Irina Arkad'evna Bondar, et al.
出版: (2015-03-01)

Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor.
由: Reimann, F, et al.
出版: (1999)